Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1
| Autor: | K. Rajender Reddy, Sylvia Hu, Lennox J. Jeffers, William M. Cassidy, Charles D. Howell |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male medicine.medical_specialty Genotype Hepatitis C virus Hepacivirus Interferon alpha-2 medicine.disease_cause Antiviral Agents Gastroenterology Polyethylene Glycols chemistry.chemical_compound Internal medicine Ribavirin medicine Humans Prospective Studies Adverse effect Prospective cohort study Interferon alfa Aged Hepatology biology business.industry Interferon-alpha virus diseases Hepatitis C Chronic Middle Aged biology.organism_classification Recombinant Proteins digestive system diseases Black or African American chemistry Immunology Female business Peginterferon alfa-2a medicine.drug |
| Zdroj: | Hepatology. 39:1702-1708 |
| ISSN: | 1527-3350 0270-9139 |
| DOI: | 10.1002/hep.20212 |
| Popis: | Black Americans (blacks) have a high prevalence of chronic hepatitis C virus (HCV) infection and respond poorly to therapy with interferon alfa-based regimens, but they have been underrepresented in clinical trials. The aim of this study was to assess the rate of sustained virological response (SVR) to peginterferon alfa-2a (40 kd) in combination with ribavirin in black patients chronically infected with HCV genotype 1. In a prospective, multicenter, open-label trial, 78 black and 28 white American interferon-naive patients were enrolled to receive once weekly subcutaneous injections of 180 μg peginterferon alfa-2a plus oral ribavirin (1000 mg/d for patients weighing less than 75 kg and 1200 mg/d for patients weighing 75 kg or more) for 48 weeks. Pre- and post-treatment liver biopsies were evaluated for necroinflammation and fibrosis. SVR, defined as undetectable ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text